Galera Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
Hello, everyone. My name is Boobalan Pachaiyappan and I'm Vice President and senior biopharma analyst at H.C. Wainwright. With me today is Dr. Mel Sorensen, who is the President and Chief Executive Officer of Galera Therapeutics.
For those who are new to the story, Galera is focused on developing novel drugs and transform the radiotherapy for patients with cancer. So, Mel, welcome to the show.
Thank you, Boobalan.
Yeah. So the purposes of today's discussion, we are going to discuss three topics of interest. So, first, we are going to discuss about avasopasem and the most recent CRL that you got. And then the second one, we will shift our attention towards rucosopasem, that's your emerging interest. And finally, future directions for Galera.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
